瘦型非酒精性脂肪性肝病的发病机制研究进展
Research Progress on the Pathogenesis of Lean Non-Alcoholic Fatty Liver Disease
DOI: 10.12677/acm.2025.1592486, PDF,   
作者: 李勤荣：西双版纳傣族自治州人民医院消化内科，云南 西双版纳
关键词: 非酒精性脂肪性肝病；发病机制；瘦型；Non-Alcoholic Fatty Liver Disease； Pathogenesis； Lean
摘要: 瘦型非酒精性脂肪肝病(Lean Non-Alcoholic Fatty Liver Disease, lean NAFLD)是指在体重指数(Body Mass Index, BMI)正常或偏低人群中发生的非酒精性脂肪肝病(NAFLD)。尽管传统观点认为NAFLD主要与肥胖相关，但近年来发现，并非所有NAFLD患者都伴随体重超标，这一部分患者日益受到关注。而lean NAFLD的发病机制复杂，呈现出代谢–免疫–遗传多维度交互特征，涉及脂质代谢异常、胰岛素抵抗、肠道微生物群失调、遗传易感性及炎症反应等多方面因素。本文旨在综述当前关于lean NAFLD发病机制的研究进展，分析其与肥胖相关NAFLD (obese NAFLD)的异同，并探讨未来研究方向。
Abstract: Lean Non-alcoholic Fatty Liver Disease (lean NAFLD) refers to non-alcoholic fatty liver disease (NAFLD) that occurs in individuals with normal or low body mass index (BMI). Although traditional views suggest that NAFLD is mainly associated with obesity, it has been found in recent years that not all NAFLD patients are accompanied by overweight, and this group of patients is receiving increasing attention. The pathogenesis of lean NAFLD is complex, exhibiting multidimensional interactions of metabolism, immunity, and genetics, involving various factors such as abnormal lipid metabolism, insulin resistance, dysbiosis of gut microbiota, genetic susceptibility, and inflammatory response. This article aims to review the current research progress on the pathogenesis of lean NAFLD, analyze its similarities and differences with obesity related NAFLD, and explore future research directions.
文章引用：李勤荣. 瘦型非酒精性脂肪性肝病的发病机制研究进展[J]. 临床医学进展, 2025, 15(9): 274-279. https://doi.org/10.12677/acm.2025.1592486

参考文献

[1] 中华医学会肝病学分会. 代谢相关(非酒精性)脂肪性肝病防治指南(2024年版) [J]. 中华肝脏病杂志, 2024, 32(5): 418-434.
[2] Tian, H., Zhang, K., Hui, Z., Ren, F., Ma, Y., Han, F., et al. (2023) Global Burden of Non-Alcoholic Fatty Liver Disease in 204 Countries and Territories from 1990 to 2019. Clinics and Research in Hepatology and Gastroenterology, 47, Article ID: 102068. [Google Scholar] [CrossRef] [PubMed]
[3] Riazi, K., Azhari, H., Charette, J.H., Underwood, F.E., King, J.A., Afshar, E.E., et al. (2022) The Prevalence and Incidence of NAFLD Worldwide: A Systematic Review and Meta-Analysis. The Lancet Gastroenterology & Hepatology, 7, 851-861. [Google Scholar] [CrossRef] [PubMed]
[4] Devarbhavi, H., Asrani, S.K., Arab, J.P., Nartey, Y.A., Pose, E. and Kamath, P.S. (2023) Global Burden of Liver Disease: 2023 Update. Journal of Hepatology, 79, 516-537. [Google Scholar] [CrossRef] [PubMed]
[5] Quek, J., Chan, K.E., Wong, Z.Y., Tan, C., Tan, B., Lim, W.H., et al. (2023) Global Prevalence of Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis in the Overweight and Obese Population: A Systematic Review and Meta-Analysis. The Lancet Gastroenterology & Hepatology, 8, 20-30. [Google Scholar] [CrossRef] [PubMed]
[6] Ye, Q., Zou, B., Yeo, Y.H., Li, J., Huang, D.Q., Wu, Y., et al. (2020) Global Prevalence, Incidence, and Outcomes of Non-Obese or Lean Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. The Lancet Gastroenterology & Hepatology, 5, 739-752. [Google Scholar] [CrossRef] [PubMed]
[7] Rinella, M.E., Neuschwander-Tetri, B.A., Siddiqui, M.S., Abdelmalek, M.F., Caldwell, S., Barb, D., et al. (2023) AASLD Practice Guidance on the Clinical Assessment and Management of Nonalcoholic Fatty Liver Disease. Hepatology, 77, 1797-1835. [Google Scholar] [CrossRef] [PubMed]
[8] Long, M.T., Noureddin, M. and Lim, J.K. (2022) AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review. Gastroenterology, 163, 764-774.e1. [Google Scholar] [CrossRef] [PubMed]
[9] Kahn, C.R., Wang, G. and Lee, K.Y. (2019) Altered Adipose Tissue and Adipocyte Function in the Pathogenesis of Metabolic Syndrome. Journal of Clinical Investigation, 129, 3990-4000. [Google Scholar] [CrossRef] [PubMed]
[10] Azzu, V., Vacca, M., Virtue, S., Allison, M. and Vidal-Puig, A. (2020) Adipose Tissue-Liver Cross Talk in the Control of Whole-Body Metabolism: Implications in Nonalcoholic Fatty Liver Disease. Gastroenterology, 158, 1899-1912. [Google Scholar] [CrossRef] [PubMed]
[11] Perfield, J.W., Ortinau, L.C., Pickering, R.T., Ruebel, M.L., Meers, G.M. and Rector, R.S. (2013) Altered Hepatic Lipid Metabolism Contributes to Nonalcoholic Fatty Liver Disease in Leptin-Deficient Ob/Ob Mice. Journal of Obesity, 2013, Article ID: 296537. [Google Scholar] [CrossRef] [PubMed]
[12] Montagner, A., Polizzi, A., Fouché, E., Ducheix, S., Lippi, Y., Lasserre, F., et al. (2016) Liver PPARα Is Crucial for Whole-Body Fatty Acid Homeostasis and Is Protective against NAFLD. Gut, 65, 1202-1214. [Google Scholar] [CrossRef] [PubMed]
[13] Shinozaki, S., Tahara, T., Miura, K., Kawarai Lefor, A. and Yamamoto, H. (2022) Pemafibrate Therapy for Non-Alcoholic Fatty Liver Disease Is More Effective in Lean Patients than Obese Patients. Clinical and Experimental Hepatology, 8, 278-283. [Google Scholar] [CrossRef] [PubMed]
[14] Phipps, M. and Wattacheril, J. (2019) Non-Alcoholic Fatty Liver Disease (NAFLD) in Non-Obese Individuals. Frontline Gastroenterology, 11, 478-483. [Google Scholar] [CrossRef] [PubMed]
[15] Ahadi, M., Molooghi, K., Masoudifar, N., Namdar, A.B., Vossoughinia, H. and Farzanehfar, M. (2020) A Review of Non‐Alcoholic Fatty Liver Disease in Non‐Obese and Lean Individuals. Journal of Gastroenterology and Hepatology, 36, 1497-1507. [Google Scholar] [CrossRef] [PubMed]
[16] Feldman, A., Eder, S.K., Felder, T.K., Kedenko, L., Paulweber, B., Stadlmayr, A., et al. (2017) Clinical and Metabolic Characterization of Lean Caucasian Subjects with Non-Alcoholic Fatty Liver. American Journal of Gastroenterology, 112, 102-110. [Google Scholar] [CrossRef] [PubMed]
[17] Fabbrini, E., Sullivan, S. and Klein, S. (2010) Obesity and Nonalcoholic Fatty Liver Disease: Biochemical, Metabolic, and Clinical Implications. Hepatology, 51, 679-689. [Google Scholar] [CrossRef] [PubMed]
[18] Feng, R., Luo, C., Li, C., Du, S., Okekunle, A.P., Li, Y., et al. (2017) Free Fatty Acids Profile among Lean, Overweight and Obese Non-Alcoholic Fatty Liver Disease Patients: A Case-Control Study. Lipids in Health and Disease, 16, Article No. 165. [Google Scholar] [CrossRef] [PubMed]
[19] Park, H., Yoon, E.L., Chung, G.E., Choe, E.K., Bae, J.H., Choi, S.H., et al. (2023) Genetic and Metabolic Characteristics of Lean Nonalcoholic Fatty Liver Disease in a Korean Health Examinee Cohort. Gut and Liver, 18, 316-327. [Google Scholar] [CrossRef] [PubMed]
[20] Anirvan, P., Khan, Z.H., Bhuyan, P., Dixit, S., Dash, R., Mishra, P., et al. (2025) Gut Microbiota and Genetic Polymorphisms Appear to Drive Disease Expression of Nonalcoholic Fatty Liver Disease in Lean Individuals. Journal of Clinical and Experimental Hepatology, 15, Article ID: 102503. [Google Scholar] [CrossRef] [PubMed]
[21] Bhattacharya, I., Maity, D.K., Kumar, A., Sarkar, S., Bhattacharya, T., Sahu, A., et al. (2025) Beyond Obesity: Lean Metabolic Dysfunction-Associated Steatohepatitis from Unveiling Molecular Pathogenesis to Therapeutic Advancement. Naunyn-Schmiedeberg’s Archives of Pharmacology. [Google Scholar] [CrossRef] [PubMed]
[22] Lu, C., Chou, T., Wu, T., Lee, Y., Yang, H. and Huang, K. (2025) PNPLA3 and SAMM50 Variants Are Associated with Lean Nonalcoholic Fatty Liver Disease in Asian Population. Annals of Hepatology, 30, Article ID: 101761. [Google Scholar] [CrossRef] [PubMed]
[23] Welty, F.K. (2020) Hypobetalipoproteinemia and Abetalipoproteinemia: Liver Disease and Cardiovascular Disease. Current Opinion in Lipidology, 31, 49-55. [Google Scholar] [CrossRef] [PubMed]
[24] Sürücü Kara, İ., Köse, E., Mutlu, H., et al. (2025) Clinical and Biochemical Spectrum of APOB-Related Hypobetalipoproteinemia: Insights from a Retrospective Cohort Study. Journal of Clinical Lipidology, 19, 605-616. [Google Scholar] [CrossRef] [PubMed]
[25] Vallianou, N.G., Kounatidis, D., Psallida, S., Vythoulkas-Biotis, N., Adamou, A., Zachariadou, T., et al. (2024) NAFLD/MASLD and the Gut-Liver Axis: From Pathogenesis to Treatment Options. Metabolites, 14, Article No. 366. [Google Scholar] [CrossRef] [PubMed]
[26] Zhang, W., Cheng, W., Li, J., Huang, Z., Lin, H. and Zhang, W. (2024) New Aspects Characterizing Non-Obese NAFLD by the Analysis of the Intestinal Flora and Metabolites Using a Mouse Model. mSystems, 9, e0102723. [Google Scholar] [CrossRef] [PubMed]
[27] Xue, L., Deng, Z., Luo, W., He, X. and Chen, Y. (2022) Effect of Fecal Microbiota Transplantation on Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial. Frontiers in Cellular and Infection Microbiology, 12, Article ID: 759306. [Google Scholar] [CrossRef] [PubMed]
[28] Iino, C., Endo, T., Iino, K., Tateda, T., Sato, S., Igarashi, G., et al. (2022) Reduced Equol Production and Gut Microbiota Features in Men with Lean Nonalcoholic Fatty Liver Disease. American Journal of Men’s Health, 16, 1-14. [Google Scholar] [CrossRef] [PubMed]
[29] Banaszczak, M. and Stachowska, E. (2017) NAFLD Pathogenesis in the Light of Recent Research. Postępy Biochemii, 63, 190-197.
[30] Huang, X., Yao, Y., Hou, X., Wei, L., Rao, Y., Su, Y., et al. (2022) Macrophage SCAP Contributes to Metaflammation and Lean NAFLD by Activating STING-NF-κB Signaling Pathway. Cellular and Molecular Gastroenterology and Hepatology, 14, 1-26. [Google Scholar] [CrossRef] [PubMed]
[31] Rotundo, L., Persaud, A., Feurdean, M., Ahlawat, S. and Kim, H. (2018) The Association of Leptin with Severity of Non-Alcoholic Fatty Liver Disease: A Population-Based Study. Clinical and Molecular Hepatology, 24, 392-401. [Google Scholar] [CrossRef] [PubMed]
[32] Lee, S., Kim, K.W., Lee, J., Park, T., Khang, S., Jeong, H., et al. (2021) Visceral Adiposity as a Risk Factor for Lean Non‐alcoholic Fatty Liver Disease in Potential Living Liver Donors. Journal of Gastroenterology and Hepatology, 36, 3212-3218. [Google Scholar] [CrossRef] [PubMed]
[33] Asgari-Taee, F., Zerafati-Shoae, N., Dehghani, M., Sadeghi, M., Baradaran, H.R. and Jazayeri, S. (2018) Association of Sugar Sweetened Beverages Consumption with Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. European Journal of Nutrition, 58, 1759-1769. [Google Scholar] [CrossRef] [PubMed]
[34] Assy, N., Nasser, G., Kamayse, I., Nseir, W., Beniashvili, Z., Djibre, A., et al. (2008) Soft Drink Consumption Linked with Fatty Liver in the Absence of Traditional Risk Factors. Canadian Journal of Gastroenterology, 22, 811-816. [Google Scholar] [CrossRef] [PubMed]

为你推荐